When David R. Tabatadze’s small biotechnology venture ran out of money in 2013, he almost gave up on it.
He went to pharmaceutical companies and “angel” investors, those individuals willing to put modest amounts of money into new businesses. None were interested in funding his research into potential genetic medicines.